膀胱癌组织中OLA1、BARD1表达水平及临床预后意义

Expression levels of OLA1 and BARD1 in bladder cancer tissues and their clinical prognostic significance

目的分析膀胱癌组织中Obg样ATPase 1(OLA1)、乳腺癌基因1相关环指结构域蛋白1(BARD1)的表达水平及临床预后意义。方法选取2014年3月至2017年3月经本院确诊并进行手术治疗的80例膀胱癌患者的癌组织(癌组织组)与距肿瘤边缘4 cm处的癌旁组织标本(癌旁组织组)作为研究对象。根据免疫组化染色结果, 将膀胱癌组织分为OLA1高表达组(52例)、OLA1低表达组(28例)、BARD1高表达组(50例)和BARD1低表达组(30例)。分析OLA1、BARD1表达水平与膀胱癌患者的临床病理特征的关系, 采用Cox回归分析探讨影响膀胱癌患者预后的相关因素。结果 OLA1、BARD1在癌组织组的高表达率(65.00%、62.50%)均明显高于癌旁组织(41.25%、43.75%)(均P<0.05)。OLA1、BARD1高、低表达组患者的年龄、性别、肿瘤长径比较, 差异均无统计学意义(均P>0.05);OLA1、BARD1高表达组的病理分级、临床分期T2~T4、淋巴转移、复发患者多于OLA1、BARD1低表达组, 差异均有统计学意义(均P<0.05)。OLA1高表达、低表达组患者的5年存活率分别为30.77%(16/52)、89.29%(25/28), BARD1高表达、低表达组患者的5年存活率分别为30.00%(15/50)、86.67%(26/30), OLA1、BARD1高表达组与低表达组的5年存活率比较, 差异均有统计学意义(P<0.05)。单因素分析得出:病理分级、临床分期、淋巴结转移、是否复发以及OLA1、BARD1表达水平均与膀胱癌患者的预后密切相关(均P<0.05)。多因素Cox回归分析得出:淋巴转移、高级别病理分级、T2~T4临床分期、复发、OLA1高表达、BARD1高表达均为影响膀胱癌患者预后的独立危险因素(均P<0.05)。结论膀胱癌组织中OLA1、BARD1均呈高表达, 且表达水平与患者病理分级、临床分期、淋巴转移、是否复发显著相关, 可作为预测膀胱癌患者预后的肿瘤标志物。

Objective To explore the expression levels and clinical prognostic significance of Obg-like ATPase 1(OLA1)and BRCA1-associated RING domain-1(BARD1)in bladder cancer tissues and their clinical prognostic significance.Methods From March 2014 to March 2017,80 patients with bladder cancer who were diagnosed and underwent surgical treatment in our hospital were selected as the study objects,including cancer tissues(cancer tissue group)and para-cancer tissue specimens 4 cm away from the tumor margin(para-cancer tissue group).According to the results of immunohistochemical staining,bladder cancer tssues were divided into OLA1 high expression group(52 cases),OLA1 low expression group(28 cases),BARD1 high expression group(50 cases)and BARD1 low expression group(30 cases).The relationship between the expression levels of OLA1 and BARDl and the clinicopathological features of patients with bladder cancer was analyzed,and the prognostic factors of patients with bladder cancer were investigated by Cox regression analysis.Results The high expression rates of OLAl and BARD1 in cancer tissue group(65.00%,62.50%)were significantly higher than those in para-cancer tissue group(41.25%,43.75%)(P<0.05).There was no statistical significance in OLA1 and BARDI1 expression groups with different age,gender and tumor length diameter(all P>0.05).There were more patients with pathological grade,clinical stage T2-T4,lymphatic metastasis and recurrence in the OLA1 and BARD1 high expression group than in the OLAl and BARDI low expression group,and the differences were statistically significant(all P<0.05).The 5-year survival rates of patients with high and low expression group of OLA1 were 30.77%(16/52)and 89.29%(25/28),respectively.The 5-year survival rates of patients with high and low expression group of BARDI were 30.00%(15/50)and 86.67%(26/30).There were significant differences in 5-year survival rate between high and low expression group of OLA1 and BARD1(P<0.05).Univariate analysis showed that pathological grade,clinical stage,lymph node metastasis,recurrence and OLA1 and BARD1 expression levels were closely related to the prognosis of patients with bladder cancer(all P<0.05).Multivariate Cox regression analysis showed that lymphatic metastasis,high-grade pathological grade,T2-T4 clinical stage,recurrence,OLA1 high expression,BARD1 high expression were independent risk factors affecting the prognosis of patients with bladder cancer(all P<0.05).Conclusions OLA1 and BARDI are highly expressed in bladder cancer tissues,and the expression levels are significantly correlated with the pathological grade,clinical stage,lymphatic metastasis,and whether or not there is recurrence of the patients,which can be used as tumor markers to predict the prognosis of patients with bladder cancer.